Lastly, considering that LKB1 is frequently mutated or deleted in various cancers, we analyzed the response of LKB1-deficient cells to YM155, a small imidazolium-based compound that blocks survivin expression via transcriptional inhibition of the survivin gene promoter [37–39]. This evidence concerns the gene BIRC5 and cancer.